文献速递乳腺癌

TRADE II期试验:早期HR阳性/HER2阴性乳腺癌中阿贝西利剂量递增的耐受性评估

TRADE: a phase II trial to assess the tolerability of abemaciclib dose escalation in early-stage HR-positive/HER2-negative breast cancer.
PubMed 文献 · Ann Oncol · 2025-10-17

TRADE是一项前瞻性单臂II期研究,评估早期高危淋巴结阳性HR阳性/HER2阴性乳腺癌患者辅助阿贝西利采用剂量递增策略(50→100→150 mg每日两次)能否改善耐受性。主要终点为12周时因任何原因停药或无法达到/维持目标剂量的复合率。89例可评估患者中该复合率为29.2%(90%CI 21.3%–38.2%,P=0.023),显著低于monarchE历史值40%,70.8%患者达到并维持150 mg每日两次。

要点

  • 剂量递增策略12周复合终点率29.2%,低于monarchE历史值40%(P=0.023)
  • 70.8%患者达到并维持150 mg每日两次目标剂量,93.3%在12周时仍在治疗
  • 早期停药少见(6.7%),该策略可考虑用于辅助阿贝西利起始治疗

核心结论

  • 辅助阿贝西利剂量递增策略使更多患者在12周时达到并维持目标剂量,优于monarchE观察到的结果。

研究设计与样本

  • 前瞻性单臂II期研究,入组淋巴结阳性HR阳性/HER2阴性乳腺癌且适合辅助阿贝西利联合内分泌治疗的患者。
  • 给药方案为阿贝西利50 mg每日两次用2周,递增至100 mg每日两次用2周,再递增至最终剂量150 mg每日两次。
  • 剂量递增要求无持续3-4级或持续性2级毒性;主要终点为12周时因任何原因停药或无法达到/维持目标剂量的复合率。
  • 共89例可评估患者。

主要发现

  • 89例中26例(29.2%,90%CI 21.3%–38.2%,P=0.023)达到主要终点,显著低于monarchE历史值40%。
  • 达到终点的26例中,6例(6.7%)为早期停药,8例(9.0%)为无法达到150 mg,12例(13.5%)为从150 mg减量。
  • 70.8%患者达到并维持150 mg每日两次给药。
  • 93.3%患者在12周时仍在继续治疗。

关键数值与推荐

  • 主要终点复合率在12周时为29.2%(90%CI 21.3%–38.2%,P=0.023),对照monarchE历史值40%。
  • 早期停药率6.7%,无法达到150 mg率9.0%,从150 mg减量率13.5%。
  • 达到并维持150 mg每日两次的患者比例为70.8%。

临床怎么用

  • 在启动辅助阿贝西利时,可考虑采用50→100→150 mg每日两次的剂量递增策略以改善耐受性。
  • 剂量递增需在无持续3-4级或持续性2级毒性时进行。

局限性

  • 单臂设计,主要终点与monarchE历史值40%进行比较。
  • 样本量为89例可评估患者。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Adjuvant abemaciclib with endocrine therapy (ET) improves clinical outcomes in patients with high-risk node-positive early-stage hormone receptor-positive/HER2-negative (HR-positive/HER2-negative) breast cancer (BC), based on the monarchE trial. Patients may experience tolerability issues at the standard abemaciclib dose [150 mg twice daily (b.i.d.)], potentially leading to early treatment discontinuation, particularly within the initial weeks of therapy. TRADE is a prospective, single-arm, phase II study evaluating whether dose escalation of adjuvant abemaciclib improves drug tolerability. PATIENTS AND METHODS: Eligible patients had node-positive HR-positive/HER2-negative BC and were candidates for adjuvant abemaciclib with ET. Participants initiated abemaciclib at 50 mg b.i.d. for 2 weeks, then escalated to 100 mg b.i.d. for 2 weeks, then escalated to the final dose level (150 mg b.i.d.). Dose escalation required the absence of ongoing grade 3-4 or persistent grade 2 toxicity. The primary endpoint, measured at 12 weeks, was a composite rate of abemaciclib discontinuation for any reason or inability to reach or maintain the target dose. RESULTS: In 89 evaluable patients, the initial dose escalation strategy significantly reduced the composite rate at 12 weeks versus a historical value of 40% from monarchE. In total, 26/89 participants (29.2%, 90% confidence interval 21.3% to 38.2%, P = 0.023) met the endpoint: 6 (6.7%) for early discontinuation, 8 (9.0%) for inability to reach 150 mg, and 12 (13.5%) for dose reduction from 150 mg. The majority (70.8%) reached and maintained 150 mg b.i.d. dosing. CONCLUSION: Use of an adjuvant abemaciclib dose escalation strategy allowed more patients to reach and maintain target dosing at 12 weeks than observed in monarchE. Early discontinuation was infrequent, and 93.3% of patients were continuing therapy at 12 weeks. This dosing strategy could be considered when initiating adjuvant abemaciclib.

来源:Ann Oncol,查看原文。版权归原作者所有。

引用

  1. Mayer EL, Trapani D, Kim SE, et al. TRADE: a phase II trial to assess the tolerability of abemaciclib dose escalation in early-stage HR-positive/HER2-negative breast cancer. Ann Oncol. 2025. PMID: 41110695. doi:10.1016/j.annonc.2025.09.141

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。